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Endovascular conversion with femorofemoral
bypass as a treatment of endotension and
aneurysm sac enlargement
Stephen T. Smith, MD, G. Patrick Clagett, MD, and Frank R. Arko, MD, Dallas, Tex
We report a case of a patient treated with a Gore Excluder endograft for AAA in November 2003 with subsequent
aneurysm sac enlargement in the absence of an identified endoleak. The patient had a Type I endoleak treated with a
Palmaz stent at the neck and later developed a Type II endoleak treated with translumbar coil embolization. This was
successful with absence of pressure in the sac after the procedure and stable aneurysm size over the next nine months.
Surveillance of the patient with both CT and ultrasound then revealed an increase in the aortic sac diameter in the absence
of endoleak. A Cook Zenith converter was used to reline this PTFE endograft. Subsequently, imaging showed aneurysm
sac shrinkage. This is a report of endotension with aneurysm expansion following Gore Excluder placement which was
treated successfully with a dacron endograft. ( J Vasc Surg 2007;45:395-8.)Endovascular repair of abdominal aortic aneurysms
(EVAR) has gained widespread acceptance as an alternative
to open surgical repair. Recent randomized trials have
shown a reduction in the early (30-day) morbidity and
mortality compared with open repair.1,2 Additional proce-
dures may, however, be required for endoleak, migration or
endotension.
Endoleak is a well-described complication of EVAR
and is associated with aneurysm sac enlargement. Endoten-
sion in the absence of an endoleak is also associated with
aneurysm sac enlargement.3 Endotension has been re-
ported with use of the Gore Excluder (W. L. Gore &
Associates, Flagstaff, Ariz) and has been associated with late
surgical conversions in patients treated with this graft.4
Although the incidence of endotension with sac enlarge-
ment is low, its management remains controversial. Cur-
rent treatment includes surveillance and surgical conver-
sion.
In this report, we present a patient with an Excluder
endograft in whom endotension developed 2 years after
implantation. He was treated by placing a Dacron endo-
prosthesis within the Excluder and conversion to an aor-
touniiliac graft with femorofemoral bypass with occlusion
of the contralateral limb. Follow-up surveillance demon-
strated rapid aneurysm sac shrinkage within 6 months.
CASE REPORT
An 87-year-old man with an asymptomatic 6.2-cm abdominal
aortic aneurysm (AAA) was treated in November 2003 with an
Excluder 26-mm  14.5-mm  16-cm endograft (Fig 1). The
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doi:10.1016/j.jvs.2006.08.077initial aortic morphology included a proximal neck diameter of 21
mm and a neck length of 18 mm. The right and left common iliac
arteries were both 13 mm in diameter. On completion arteriogram
after EVAR, a small, delayed type II endoleak was noted from a
lumbar vessel. He was discharged home on postoperative day 2
without complications.
One-month surveillance computed tomography angiography
(CTA) showed a type I endoleak with mild separation of the
proximal endograft from the posterior aortic neck (Fig 2). This was
treated with a Palmaz P3110 stent (Cordis, Miami Lakes, Fla) and
dilated to 20 mm at the proximal infrarenal aortic neck, with
resolution of the type I endoleak. A 2-month surveillance CTA
demonstrated resolution of the type I endoleak with good apposi-
tion of the Palmaz stent and aortic graft to the aortic wall and a type
II endoleak without aneurysm enlargement. An 8-month surveil-
lance CTA demonstrated aneurysm sac enlargement of 5 mm, with
the same type II endoleak, which was confirmed by a duplex
ultrasound scan.
A translumbar embolization of the endoleak was successfully
performed 8-months after the implant. Pressure measurements
obtained at this procedure included a systemic pressure of 160/90
mm Hg and a sac pressure of 75/65 mm Hg, with pulsatile
backbleeding. After translumbar coil embolization of the lumbar
vessel, there was no recordable sac pressure and no backbleeding
from the catheter.
Routine surveillance with CTA and duplex ultrasound scans
was continued. During the next 6 months, two CTAs and one
duplex ultrasound scan demonstrated no endoleak and a stable
aneurysm sac size with a 6.7-cm maximal diameter. Duplex surveil-
lance 9 months after translumbar coiling and 16 months after initial
implantation demonstrated an increase in the sac diameter to 8 cm.
A CTA, including precontrast studies, was performed with 80
mL of nonionic contrast medium injected at 4 mL/s. Images were
acquired at a pitch of 6.0 with 1.25-mm nominal section thickness,
with delayed images as well. The CTA confirmed aneurysm sac
enlargement to 9.2 cm, without the presence of an endoleak (Fig
3). Because of the significant and rapid growth of the aneurysm sac,
intervention was considered necessary. Open surgical conversion
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age, chronic renal insufficiency, and limited cardiac reserve.
Endotension was believed to be the cause of sac enlargement,
and an endovascular repair with relining of the graft was per-
formed. Intravascular ultrasound (IVUS) imaging was used exten-
Fig 1. A three-dimensional reconstruction shows a 6.2-cm infra-
renal abdominal aortic aneurysm.
Fig 2. A computed tomography angiography at 1 month shows a
type I endoleak near the aneurysm neck.sively because of the patient’s renal insufficiency (baseline serumcreatinine, 2.5 mg/dL). Aortography with 40 mL of gadolinium
was used before the intervention and demonstrated no evidence of
an endoleak.
Proximally, there was poor apposition of the Palmaz stent to
the wall of the stent graft and aorta (Fig 4). This appeared to occur
over time as the aorta and self-expanding stent graft dilated over
time, while the Palmaz stent did not. There was, however, good
apposition of the stent graft to the aortic wall. The Palmaz stent
was molded with a compliant aortic balloon with improved appear-
ance on IVUS (Fig 5).
A Zenith (Cook, Indianapolis, IN) aortouniiliac converter 28
Fig 3. A computed tomography angiography 16 months after
endovascular aneurysm repair shows aneurysm growth to 9.2 cm
without a detectable endoleak.
Fig 4. An intravascular ultrasound image shows poor apposition
of the Palmaz stent to the endograft and aorta.mm  12 mm  80 mm in length was used to convert the
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completely relined with a 16-mm-diameter Cook limb. The right
limb of the Excluder endograft was then occluded with a 24 mm
20 mm Cook occluder and four proximal platinum coils. A femo-
rofemoral crossover graft was then performed using ringed ex-
panded polytetrafluoroethylene. The procedure was well tolerated,
and the patient was discharged on postoperative day 2.
A CTA 2 weeks after operation showed no endoleak and a
slightly decreased aneurysm sac of 9.1 cm. Noncontrast CTA and
duplex ultrasound imaging 6 months later demonstrated no en-
doleak and a markedly reduced aneurysm sac measuring 5.5 cm in
greatest diameter, a decrease of 41 mm (Fig 6).
DISCUSSION
The purpose of EVAR is to prevent AAA rupture and
aneurysm-related death. Aneurysm sac shrinkage after
EVAR is used as a clinical marker for successful exclusion of
the aneurysm. It does not completely prevent aneurysm
rupture, however, because aneurysm rupture in the pres-
ence of a shrinking sac has been reported.5 The presence of
an endoleak or aneurysm sac enlargement after EVAR may
require enhanced surveillance and possibly intervention.
Endoleak may be associated with sac enlargement after
EVAR; however, when cross-sectional imaging and duplex
ultrasound imaging cannot demonstrate an endoleak in the
setting of an enlarging aneurysm sac, the diagnosis of
endotension is made.
Differences in aneurysm sac morphology after EVAR
have been shown to be device-specific.6-7 In particular, the
Gore Excluder been shown to have a lower incidence of
aneurysm sac shrinkage than other currently available en-
dografts. In a recent analysis of 109 patients treated with
Fig 5. An intravascular ultrasound image after treatment shows
improved appearance.the Excluder, Melissano et al8 reported an incidence ofaneurysm sac shrinkage of only 37%. Similarly, Ouriel et al6
reported that sac shrinkage was least likely to occur with the
Excluder when device-specific outcomes were compared.
Because the incidence of endoleak is generally similar
with all devices, this difference in sac morphology associ-
ated with the Excluder is thought to be due to endotension,
possibly from pressure transmission through the porous
fabric of the Excluder. The clinical significance of endoten-
sion is unclear, with some authors suggesting a low risk of
aneurysm rupture.9 In fact, no cases of endotension-related
aneurysm rupture have been reported with the Excluder
endograft in the United States or abroad.4
The treatment for patients with endotension and an
enlarging aneurysm sac is controversial. Some authors have
recommended surgical conversion, and others have sug-
gested a nonoperative approach.10-11 This is an important
issue, because up to one third of patients treated with this
endograft may have aneurysm sac enlargement 5 mm.4
Fortunately, Gore has altered the design of the Excluder in
an attempt to decrease the porosity of the fabric layer;
however, a decrease in the incidence of endotension subse-
quent to this modification has yet to be confirmed.
Our patient initially had both type I and II endoleaks
that were treated appropriately with resolution. The type I
endoleak was treated with a Palmaz stent that was dilated
up to 20 mm, the initial diameter of the proximal aortic
neck. The type II endoleak was treated with the preferred
method of translumbar coil embolization. After this treat-
ment, sac puncture revealed no pressure within the aneu-
rysm sac.
In the study by Kong et al4 of eight patients with
delayed surgical conversion and a presumed diagnosis of
endotension, two had patent lumbar arteries and an undi-
agnosed type II endoleak. In our patient, duplex ultra-
sound imaging and five CTAs after treatment of his type II
endoleak demonstrated no further evidence of endoleak.
Fig 6. Computed tomography at 6 months after treatment shows
a markedly decreased aneurysm sac.We were thus convinced that the aneurysm sac growth in
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undiagnosed type II endoleak.
During the aortouniiliac conversion, the Palmaz stent
was also seen on IVUS to have poor apposition with the
aortic stent graft. However, there was good apposition of
the stent graft to the aortic wall. This phenomenon is often
seen late after Palmaz stent placement, as the proximal
aortic neck and the self-expanding stents of aortic stent
grafts dilate while the balloon expandable stent remains the
same diameter that it was originally dilated to.
One could argue that the patient had a history of
previous type I and II endoleaks that could have been
associated with his sac enlargement, but this seems unlikely.
The patient underwent multiple CTAs with delayed imag-
ing as well as duplex ultrasound imaging that could not
confirm any evidence of intrasac flow.
Although the Palmaz stent did have poor apposition at
the time of the conversion, there was excellent apposition
of the stent graft to the aortic wall. In addition, the relining
of the PTFE graft with the Zenith graft resulted in a rapid
decrease of 41mm in the sac size. This is consistent with what
others have reported in sac shrinkage with various grafts. 6 It
thus appears that relining the endograft with a different ma-
terial resulted in aneurysm sac shrinkage and the resolution of
endotension. This case demonstrates a minimally invasive
alternative to open surgical conversion for the treatment of
endotension associated with sac enlargement.
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